316 related articles for article (PubMed ID: 25832501)
1. Intermolecular Interactions and the Viscosity of Highly Concentrated Monoclonal Antibody Solutions.
Binabaji E; Ma J; Zydney AL
Pharm Res; 2015 Sep; 32(9):3102-9. PubMed ID: 25832501
[TBL] [Abstract][Full Text] [Related]
2. The osmotic pressure of highly concentrated monoclonal antibody solutions: effect of solution conditions.
Binabaji E; Rao S; Zydney AL
Biotechnol Bioeng; 2014 Mar; 111(3):529-36. PubMed ID: 23996891
[TBL] [Abstract][Full Text] [Related]
3. Viscosity-Lowering Effect of Amino Acids and Salts on Highly Concentrated Solutions of Two IgG1 Monoclonal Antibodies.
Wang S; Zhang N; Hu T; Dai W; Feng X; Zhang X; Qian F
Mol Pharm; 2015 Dec; 12(12):4478-87. PubMed ID: 26528726
[TBL] [Abstract][Full Text] [Related]
4. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution.
Liu J; Nguyen MD; Andya JD; Shire SJ
J Pharm Sci; 2005 Sep; 94(9):1928-40. PubMed ID: 16052543
[TBL] [Abstract][Full Text] [Related]
5. Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering.
Xu AY; Castellanos MM; Mattison K; Krueger S; Curtis JE
Mol Pharm; 2019 Oct; 16(10):4319-4338. PubMed ID: 31487466
[TBL] [Abstract][Full Text] [Related]
6. Effects of Histidine and Sucrose on the Biophysical Properties of a Monoclonal Antibody.
Baek Y; Singh N; Arunkumar A; Zydney AL
Pharm Res; 2017 Mar; 34(3):629-639. PubMed ID: 28035628
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies.
Yadav S; Shire SJ; Kalonia DS
J Pharm Sci; 2010 Dec; 99(12):4812-29. PubMed ID: 20821382
[TBL] [Abstract][Full Text] [Related]
8. Specific interactions in high concentration antibody solutions resulting in high viscosity.
Yadav S; Liu J; Shire SJ; Kalonia DS
J Pharm Sci; 2010 Mar; 99(3):1152-68. PubMed ID: 19705420
[TBL] [Abstract][Full Text] [Related]
9. Behavior of monoclonal antibodies: relation between the second virial coefficient (B (2)) at low concentrations and aggregation propensity and viscosity at high concentrations.
Saito S; Hasegawa J; Kobayashi N; Kishi N; Uchiyama S; Fukui K
Pharm Res; 2012 Feb; 29(2):397-410. PubMed ID: 21853361
[TBL] [Abstract][Full Text] [Related]
10. Predicting Protein-Protein Interactions of Concentrated Antibody Solutions Using Dilute Solution Data and Coarse-Grained Molecular Models.
Calero-Rubio C; Ghosh R; Saluja A; Roberts CJ
J Pharm Sci; 2018 May; 107(5):1269-1281. PubMed ID: 29274822
[TBL] [Abstract][Full Text] [Related]
11. Improving Viscosity and Stability of a Highly Concentrated Monoclonal Antibody Solution with Concentrated Proline.
Hung JJ; Dear BJ; Dinin AK; Borwankar AU; Mehta SK; Truskett TT; Johnston KP
Pharm Res; 2018 Apr; 35(7):133. PubMed ID: 29713822
[TBL] [Abstract][Full Text] [Related]
12. Towards an improved prediction of concentrated antibody solution viscosity using the Huggins coefficient.
Roche A; Gentiluomo L; Sibanda N; Roessner D; Friess W; Trainoff SP; Curtis R
J Colloid Interface Sci; 2022 Feb; 607(Pt 2):1813-1824. PubMed ID: 34624723
[TBL] [Abstract][Full Text] [Related]
13. Solution pH that minimizes self-association of three monoclonal antibodies is strongly dependent on ionic strength.
Sule SV; Cheung JK; Antochshuk V; Bhalla AS; Narasimhan C; Blaisdell S; Shameem M; Tessier PM
Mol Pharm; 2012 Apr; 9(4):744-51. PubMed ID: 22221144
[TBL] [Abstract][Full Text] [Related]
14. Phase separation of an IgG1 antibody solution under a low ionic strength condition.
Nishi H; Miyajima M; Nakagami H; Noda M; Uchiyama S; Fukui K
Pharm Res; 2010 Jul; 27(7):1348-60. PubMed ID: 20401522
[TBL] [Abstract][Full Text] [Related]
15. Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation.
Salinas BA; Sathish HA; Bishop SM; Harn N; Carpenter JF; Randolph TW
J Pharm Sci; 2010 Jan; 99(1):82-93. PubMed ID: 19475558
[TBL] [Abstract][Full Text] [Related]
16. Highly viscous antibody solutions are a consequence of network formation caused by domain-domain electrostatic complementarities: insights from coarse-grained simulations.
Buck PM; Chaudhri A; Kumar S; Singh SK
Mol Pharm; 2015 Jan; 12(1):127-39. PubMed ID: 25383990
[TBL] [Abstract][Full Text] [Related]
17. Molecular Computations of Preferential Interaction Coefficients of IgG1 Monoclonal Antibodies with Sorbitol, Sucrose, and Trehalose and the Impact of These Excipients on Aggregation and Viscosity.
Cloutier T; Sudrik C; Mody N; Sathish HA; Trout BL
Mol Pharm; 2019 Aug; 16(8):3657-3664. PubMed ID: 31276620
[TBL] [Abstract][Full Text] [Related]
18. Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - prediction of viscosity through protein-protein interaction measurements.
Neergaard MS; Kalonia DS; Parshad H; Nielsen AD; Møller EH; van de Weert M
Eur J Pharm Sci; 2013 Jun; 49(3):400-10. PubMed ID: 23624326
[TBL] [Abstract][Full Text] [Related]
19. Bulky Polar Additives That Greatly Reduce the Viscosity of Concentrated Solutions of Therapeutic Monoclonal Antibodies.
Larson AM; Weight AK; Love K; Bonificio A; Wescott CR; Klibanov AM
J Pharm Sci; 2017 May; 106(5):1211-1217. PubMed ID: 28137697
[TBL] [Abstract][Full Text] [Related]
20. Elucidating the weak protein-protein interaction mechanisms behind the liquid-liquid phase separation of a mAb solution by different types of additives.
Wu G; Wang S; Tian Z; Zhang N; Sheng H; Dai W; Qian F
Eur J Pharm Biopharm; 2017 Nov; 120():1-8. PubMed ID: 28754261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
